HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TummyZen Firm Appeals After Heartburn Claims Don't Settle Well In NAD Review

Executive Summary

Eli Consumer Healthcare is latest supplement marketer National Advertising Division has advised that tests of separate ingredients do not support claims for a whole product. Following NADs review of TummyZen claims on challenge by Tums firm GlaxoSmithKline, Eli Consumer appeals NAD's recommendations to discontinue claims that its supplement “stops acid production,” is “acid inhibiting,” “halts the secretion of chloride ions in your parietal cells to regulate the release of acid into your stomach,” “supports stomach lining” and is “long lasting."

You may also be interested in...



No Relief For TummyZen Heartburn Claims In Industry-Self Regulation Forum

Eli Nutrition fails in appeal of NAD review of claims for its TummyZen heartburn relief product, with a panel of the National Advertising Review Board concluding the firm overstated its product’s benefits.

Androzene Male Enhancement Product Ad Claims Fail To Withstand NAD Review

Health Club Diet discontinues challenged claims for Androzene male enhancement supplement after NAD criticizes firm for relying on studies on ingredients, not the product. Council for Responsible Nutrition challenged claims as stating an indication for erectile dysfunction drug.

TummyZen Heartburn Remedy: Health And Wellness New Products Roundup

First heartburn remedy with zinc; Invia targets optimal mental energy; and Tauriga rolls with RolLeaf plan.

Topics

Related Companies

UsernamePublicRestriction

Register

RS139915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel